Search Results
Lower-risk MDS in 2021: luspatercept, imetelstat & roxadustat
Improving the treatment of low-risk MDS: luspatercept, treatment sequencing & disease classification
The promise of luspatercept for the treatment of lower-risk MDS
Imetelstat in heavily-transfused lower-risk R/R MDS
COMMANDS trial: luspatercept vs epoetin alfa in lower-risk MDS
Promising agents under investigation for low and high-risk MDS
Key clinical trials in high-risk and low-risk MDS
IMerge subgroup study: imetelstat in patients with LR-MDS previously exposed to ESAs
Overall survival of patients following treatment with luspatercept in the MEDALIST trial
The optimal treatment of lower risk MDS
Treatment algorithm for low-risk MDS
Novel therapies in low-risk MDS
